mltx: the income statement

MyFinsight

MoonLake Immunotherapeutics (MLTX)

For the quarter ending 2025-06-30, MLTX made $5,948K in revenue. -$55,220K in net income. Net profit margin of -928.38%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Income tax expense	95
Other income, net	6,779
Research and development	49,762
General and administrative	10,936
Total operating expenses	60,698
Operating loss	-60,698
Interest expense	2,037
Loss before income tax	-55,956
Net loss	-56,051
Of which net loss attributable to noncontrolling interests shareholders	-831
Of which net loss attributable to controlling interests shareholders	-55,220

Basic net loss per share attributable to controlling interest shareholders (usd per share)	-0.87
Diluted net loss per share attributable to controlling interest shareholders (usd per share)	-0.87
Weighted-average number of class a ordinary shares, basic (in shares)	63,282,728
Weighted-average number of class a ordinary shares, diluted (in shares)	63,282,728

Unit: Thousand (K) dollars (except for numbers of shares and EPS)